Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · Real-Time Price · USD
5.07
0.00 (0.00%)
Sep 3, 2025, 4:00 PM - Market closed
Alterity Therapeutics Employees
Alterity Therapeutics had 9 employees as of June 30, 2025. The number of employees decreased by 1 or -10.00% compared to the previous year.
Employees
9
Change (1Y)
-1
Growth (1Y)
-10.00%
Revenue / Employee
$396,200
Profits / Employee
-$884,914
Market Cap
78.41M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Jun 30, 2025 | 9 | -1 | -10.00% |
Jun 30, 2024 | 10 | -1 | -9.09% |
Jun 30, 2023 | 11 | -1 | -8.33% |
Jun 30, 2022 | 12 | 1 | 9.09% |
Jun 30, 2021 | 11 | -1 | -8.33% |
Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ATHE News
- 2 days ago - Alterity Therapeutics to Present at the Biotech Showcase - GlobeNewsWire
- 5 weeks ago - Appendix 4C – Q4 FY25 Quarterly Cash Flow Report - GlobeNewsWire
- 5 weeks ago - Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy - GlobeNewsWire
- 6 weeks ago - Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study - GlobeNewsWire
- 2 months ago - Alterity Therapeutics to Provide Corporate Update in Fireside Chat - GlobeNewsWire
- 4 months ago - Alterity Therapeutics Prominently Featured at the International MSA Congress - GlobeNewsWire
- 4 months ago - Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress - GlobeNewsWire
- 4 months ago - Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy - GlobeNewsWire